Luciferases are widely used to monitor biological processes. Here we describe the naturally secreted Gaussia princeps luciferase (Gluc) as a highly sensitive reporter for quantitative assessment of cells in vivo by measuring its concentration in blood. The Gluc blood assay complements in vivo bioluminescence imaging, which has the ability to localize the signal and provides a multifaceted assessment of cell viability, proliferation and location in experimental disease and therapy models.
Luciferases are widely used to monitor biological processes. Here we describe the naturally secreted Gaussia princeps luciferase (Gluc) as a highly sensitive reporter for quantitative assessment of cells in vivo by measuring its concentration in blood. The Gluc blood assay complements in vivo bioluminescence imaging, which has the ability to localize the signal and provides a multifaceted assessment of cell viability, proliferation and location in experimental disease and therapy models.
Luciferase-mediated bioluminescence imaging has served as a reporting tool for monitoring various biological processes in vitro and in vivo in different fields [1] [2] [3] , including immunology 4 oncology 5 , virology 6 and neuroscience 7 . After systemic substrate injection, a charge-coupled device (CCD) camera can be used to localize the luciferase photon signals in vivo. Recently we have characterized a naturally secreted luciferase from the marine copepod G. princeps, Gluc, and found it to be over 2,000-fold more sensitive than luciferases from Photinus and Renilla reniformis, and 20,000-fold more sensitive than secreted alkaline phosphatase (SEAP) when expressed in mammalian cells 8, 9 . Gluc expression can be easily quantified in cell-free, conditioned medium by adding its substrate coelenterazine and measuring emitted photons using a luminometer. As Gluc is secreted from mammalian cells in culture 9 , we hypothesized that it might also be secreted into the blood of animals harboring cells expressing this reporter.
To assess the potential of Gluc as a reporter to monitor biological processes by measuring its concentration in the blood of small animals, we transduced Gli36 human glioma cells with a lentivirus vector encoding Gluc (Gli36-Gluc) and implanted different amounts of these cells into the flanks of nude mice. We visualized the tumors 3 d after implantation by in vivo bioluminescence imaging after intravenous injection of the Gluc substrate coelenterazine (4 mg/kg body weight), acquiring photon counts using a CCD camera (Fig. 1a) . At the same time, we collected 5-ml blood samples from these mice, directly aliquoted them into tubes containing 1 ml of 20 mM EDTA, and measured the Gluc activity by adding coelenterazine (100 mM) and acquiring photon counts using a luminometer (Supplementary Methods online). The Gluc activity in the blood was linear with respect to cell number in a range covering over five orders of magnitude and correlated well with values obtained using the CCD camera (Fig. 1b) . Also, we were able to detect Gluc activity in the urine, albeit to a lesser extent than in the blood, which indicates it is cleared by the kidneys (Fig. 1b) . Additionally, there was no detrimental effect of EDTA on Gluc activity measured in blood ( Supplementary Fig. 1a online) , and we did not detect substantial differences between the Gluc activity measured in serum or whole blood samples, showing that hemoglobin, which can interfere with luciferase measurement 10 , did not have an effect on Gluc activity under our assay conditions ( Supplementary Fig. 1b) . Gluc samples could be stored at 4 1C for several days without substantial decay of activity, with Gluc half-life being around 6 d ( Supplementary Fig. 2a online) . Additionally, the half-life of Gluc in the circulatory system in vivo is approximately 20 min ( Supplementary Fig. 2b ), suggesting only a minor contribution of Gluc accumulation over time to the total Gluc signal measured in blood samples.
We next compared the Gluc blood assay to an assay using secreted alkaline phosphatase (SEAP), a well-established marker monitored in serum 11 . We coinfected (490%) Gli36 cells with two different lentivirus vectors: one carrying the expression cassette for Gluc and cerulean fluorescent protein (CFP) separated by an internal ribosomal entry site element, and the other with a similar cassette encoding SEAP and mCherry, both driven by the CMV promoter ( Fig. 1c and Supplementary Methods). We implanted different amounts of these cells subcutaneously in the flanks of nude mice and assayed the Gluc activity in 5-ml blood samples, as above, and SEAP activity in 5-ml serum samples as described 11 ( Fig. 1d) . The Gluc blood assay was over 1,000-fold more sensitive than the SEAP assay: we detected 1,000 cells in vivo with signal/ background (S/B) of 20 using the Gluc blood assay and only 500,000 cells with S/B of 10 using the SEAP assay. The Gluc assay was linear with respect to cell number in a range covering over five orders of magnitude, whereas the SEAP assay fluctuated over three orders of magnitude with a plateau at around one million cells, which could lead to greater underestimation of cell number. Although the Gluc assay can be carried out with equal efficiency in blood or serum samples in a few seconds, SEAP activity cannot be measured in blood because hemoglobin inhibits it. Also SEAP assay requires B2 h handling before measurement. Gluc activity can be measured in urine, but at no time point were we able to detect SEAP activity in the urine (data not shown). Gluc has a short half-life of 20 min in the blood allowing dynamic events to be monitored, whereas the half-life of SEAP is 3 h (ref. 11), leading to accumulation over time. With the Gluc assay, in vivo bioluminescence imaging can also be used to localize Gluc-expressing cells in an animal, given that sufficient cells are present at one location, but SEAP does not have this added advantage.
To determine whether Gluc activity in the blood could be used to monitor tumor growth and therapy in vivo, we implanted nude mice subcutaneously with one million Gli36-Gluc cells. We monitored tumor growth at different time points both with a CCD camera after intravenous injection of coelenterazine or by assaying 5-ml blood samples for Gluc activity using a luminometer. At day 10 and 13 after implantation, we injected one set of mice intratumorally with an oncolytic HSV virus (hrR3; 10 8 plaque-forming units) 12 and a parallel control set with phosphate-buffered saline (PBS). The Gluc signal in the blood from tumors treated with the oncolytic virus decreased dramatically, confirming its anti-tumor activity, whereas the signal from tumors treated with PBS increased logarithmically over time, with correlative changes in tumor volume in the CCD camera images (Fig. 1e,f) . These results indicate that the Gluc concentration in the blood can serve as a quantitative marker for the number of tumor cells expressing Gluc in vivo, with complementary localization of the signal using a CCD camera.
To evaluate the usefulness of the Gluc blood assay to monitor tumor growth in deep tissues, we stereotactically injected 100,000
Gli36-Gluc cells into the brains of nude mice and monitored tumor volume over time using the CCD camera ( Fig. 2a and Supplementary Methods). At the same time, we measured Gluc activity in the blood, which showed increasing signal over time, indicating that Gluc can pass through the brain-tumor barrier, allowing the easy monitoring of tumor growth in the brain from peripheral blood samples (Fig. 2b) . The brain-tumor barrier is more permeable, however, than the blood-brain barrier, so Gluc exit from normal brain into the circulation might be more restricted.
To determine the usefulness of the Gluc blood assay to monitor gene transfer in vivo, we implanted Gli36 tumors subcutaneously in nude mice and injected them with either a lentivirus vector carrying the expression cassette for Gluc and CFP, or with PBS (Supplementary Methods). We observed a clear increase in the Gluc blood values after viral transduction, indicating that stable gene transfer had occurred with inheritance to daughter cells (Fig. 2c) . We localized the Gluc signal to the tumor by in vivo bioluminescence imaging and confirmed gene transfer by analysis of tumor sections for CFP fluorescence (Fig. 2d) . These results show that the Gluc blood assay can also be used to monitor gene transfer and proliferative fate of transduced tumor cells and thus serve as an index of gene therapy. This type of analysis could be extended for quantitative assessment of replication of virus vectors with applications in virology and vaccination. To evaluate whether the Gluc blood assay could be used to monitor circulating cells in vivo, we injected nude mice systemically (intravenously) with one million C17.2 neuronal precursor cells (NPCs) expressing Gluc and CFP (Fig. 2e) and monitored Gluc activity in 20-ml aliquots of blood over time. Mice injected with NPC-Gluc cells showed an initial high Gluc value, which decreased after 3 d, indicating that a substantial number of the NPCs survived the injection procedure. By 4 d after injection the amount of Gluc stabilized, indicating that the surviving cells were maintained but did not proliferate (Fig. 2f) . We were not able to localize a Gluc signal by CCD camera imaging anywhere in the body, suggesting that the NPCs did not concentrate in any one tissue (Fig. 2e) . These results show that the Gluc blood assay can be used to monitor circulating cell viability in vivo and, as such, could be extended to monitor stem-cell transplantation.
Here we described the use of the Gluc reporter as a tool for quantitative assessment of different biological processes in small animals by measuring its level in the blood. The Gluc blood assay was shown to be useful in monitoring tumor growth and therapy, gene transduction as well as circulating cell survival and can be readily extended to many other applications involving luciferase-mediated bioluminescence 13 . The Gluc blood assay provides a sensitive and quantitative assessment of transduced cells in vivo, complementing in vivo bioluminescence imaging, which has the unique ability to localize the signal, and thereby greatly facilitates noninvasive monitoring of many biological processes.
Note: Supplementary information is available on the Nature Methods website. . (e,f) One million C17.2 NPCs expressing Gluc and CFP (e; left) or PBS were injected intravenously in nude mice. Gluc activity was monitored over time using the CCD camera (e; right) and in blood samples using a luminometer (f). Data shown are from a representative mouse from each set. Scale bar, 100 mm.
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